Amneal Pharmaceuticals (AMRX) Other Operating Expenses (2017 - 2026)

Amneal Pharmaceuticals' Other Operating Expenses history runs 10 years deep, the most recent figure standing at -$694000.0 for Q1 2026.

• On a quarterly basis, Other Operating Expenses changed N/A year-over-year to -$694000.0 in Q1 2026; TTM through Mar 2026 was -$577000.0, a 100.61% decrease from a year earlier, with the FY2025 full-year figure at $390000.0, down 58.06% from the prior year.
• Other Operating Expenses fell to -$694000.0 in Q1 2026 per AMRX's latest filing, from $117000.0 in the prior quarter.
• Across five years, Other Operating Expenses topped out at $249.1 million in Q4 2022 and bottomed at -$94.4 million in Q1 2024.
• The 5-year median for Other Operating Expenses is $133000.0 (2024), against an average of $18.0 million.
• Biggest YoY gain for Other Operating Expenses was 3361.74% in 2024; the steepest drop was 21751.38% in 2024.
• Year by year, Other Operating Expenses stood at $249.1 million in 2022, then tumbled by 101.18% to -$2.9 million in 2023, then soared by 3361.74% to $95.8 million in 2024, then slumped by 99.88% to $117000.0 in 2025, then sank by 693.16% to -$694000.0 in 2026.
• Per Business Quant, the three latest AMRX Other Operating Expenses figures stand at -$694000.0 (Q1 2026), $117000.0 (Q3 2025), and $95.8 million (Q4 2024).